Prestige Consumer Healthcare (NYSE:PBH) Stock Price Crosses Above Fifty Day Moving Average – Should You Sell?

Prestige Consumer Healthcare Inc. (NYSE:PBH – Get Free Report) shares crossed above its 50-day moving average during trading on Monday. The stock has a 50-day moving average of $47.32 and traded as high as $48.28. Prestige Consumer Healthcare shares last traded at $47.9880, with a volume of 531,104 shares trading hands.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. Zacks Research downgraded shares of Prestige Consumer Healthcare from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 29th. Canaccord Genuity Group cut their price objective on Prestige Consumer Healthcare from $72.00 to $70.00 and set a “buy” rating for the company in a report on Friday, November 6th. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of Prestige Consumer Healthcare in a report on Tuesday, September 22nd. One analyst has rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $67.00.

View Our Latest Report on Prestige Consumer Healthcare

Prestige Consumer Healthcare Trading Up 4.8%

The company has a fifty day moving average of $47.33 and a two-hundred day moving average of $53.02. The company has a current ratio of 2.92, a quick ratio of 1.86 and a debt-to-equity ratio of 1.08. The stock has a market capitalization of $2.40 billion, a price-to-earnings ratio of 10.76, a price-to-earnings-growth ratio of 1.53 and a beta of 0.30.

Prestige Consumer Healthcare (NYSE:PBH – Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The company reported $1.13 EPS for the quarter, beating the consensus estimate of $1.07 by $0.06. Prestige Consumer Healthcare had a return on equity of 11.28% and a net margin of 13.29%. The company had revenue of $336.31 million for the quarter, compared to the consensus estimate of $329.14 million. During the same quarter last year, the company posted $1.07 earnings per share. The company’s revenue for the quarter was up 22.7% compared to the same quarter last year. On average, research analysts expect that Prestige Consumer Healthcare Inc. will post 4.50 EPS for the current year.

Institutional Trading of Prestige Consumer Healthcare

Several hedge funds have recently added to or reduced their stakes in the business. Integrated Wealth Concepts LLC grew its holdings in Prestige Consumer Healthcare by 170.8% during the 3rd quarter. Integrated Wealth Concepts LLC now owns 14,449 shares of the company’s stock worth $663,000 after acquiring an additional 9,113 shares during the period. Cetera Investment Advisers increased its holdings in Prestige Consumer Healthcare by 12.2% in the third quarter. Cetera Investment Advisers now owns 13,263 shares of the company’s stock valued at $608,000 after purchasing an additional 1,440 shares during the last quarter. Entropy Technologies LP bought a new stake in Prestige Consumer Healthcare in the third quarter valued at about $513,000. First National Bank of Omaha lifted its stake in Prestige Consumer Healthcare by 266.2% in the third quarter. First National Bank of Omaha now owns 30,944 shares of the company’s stock valued at $1,419,000 after buying an additional 22,493 shares during the period. Finally, Marshall Wace LLP increased its stake in shares of Prestige Consumer Healthcare by 898.5% in the 3rd quarter. Marshall Wace LLP now owns 309,635 shares of the company’s stock valued at $14,203,000 after acquiring an additional 278,624 shares during the last quarter. Institutional investors own 99.95% of the company’s stock.

Prestige Consumer Healthcare Company Profile

(Get Free Report)

Prestige Consumer Healthcare, Inc. develops, markets and distributes over-the-counter health and personal-care products. Its portfolio includes brands such as Dramamine for motion sickness, Clear Eyes for eye care, Chloraseptic for sore-throat relief, Compound W for wart removal, and Summer’s Eve for feminine care. The company’s products serve categories including eye and ear care, cough and cold relief, pain relief, digestive health, and women’s health. They are sold through retail channels such as drugstores, supermarkets, mass-market retailers and online sellers.

Further Reading

Receive News & Ratings for Prestige Consumer Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prestige Consumer Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.